Efficacy of colistin and non-colistin monotherapies in multi-drug resistant acinetobacter baumannii bacteremia/sepsis

Basit Öğe Kaydı
dc.contributor.authorKarabay O.
dc.contributor.authorBatirel A.
dc.contributor.authorBalkan I.I.
dc.contributor.authorAgalar C.
dc.contributor.authorAkalin S.
dc.contributor.authorAlici O.
dc.contributor.authorAlp E.
dc.date.accessioned2024-04-24T18:46:09Z
dc.date.available2024-04-24T18:46:09Z
dc.date.issued2014
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjective: This retrospective study aimed to investigate the efficacies of colistin and non-colistin monotherapies in multi-drug resistant Acinetobacter baumannii bacteremia (MDR-AB). Materials and methods: Cases with MDR-AB from 27 tertiary-referral hospitals between January 2009 and December 2012 were included. Patients' data that were on either colistin monotherapy (CM) or non-colistin monotherapy (NCM) were compared. Mortality on Day 14 was the primary endpoint, whereas microbiological eradication and clinical outcome were the secondary ones. Results: Eighty-four cases were included in the study with 36 being in the CM group and 48 in the NCM group. Thirty-eight (45.2%) cases were male and the mean age was 60.2 years. The mean durations of pre-MDR-AB hospital stay and intensive care unit stay were 25.8 days and 20.9 days, respectively. All of the cases had fever (>38°C). The mean Pitt bacteremia score (PBS) of the patients was calculated as 6.8, APACHE 2 score as 18.9 and the Charlson co-morbidity index (CCI) as 3.7 (CM: 3.6 vs. NCM: 3.9). Twenty (55.6%) cases in the CM group and 26 cases in the NCM group (54.2%) (p=0.81) died; 9 cases in the CM group (25%) and 16 cases in the NCM group (33.3%) had treatment failure (P=0.55). Bacteriological eradication was achieved in 20 (55.6%) cases in the CM group and in 36 cases (75%) in the NCM group (P=0.061). Conclusions: No significant difference could be identified between the colistin monotherapy and non-colistin monotherapy options in MDR-AB cases with respect to the results of efficacy and 14-day mortality.en_US
dc.identifier.endpage1143en_US
dc.identifier.issn0393-6384
dc.identifier.issue5en_US
dc.identifier.scopus2-s2.0-84907520572
dc.identifier.scopusqualityN/A
dc.identifier.startpage1137en_US
dc.identifier.urihttps://hdl.handle.net/11468/25086
dc.identifier.volume30en_US
dc.indekslendigikaynakScopus
dc.language.isoenen_US
dc.publisherActa Medica Mediterraneaen_US
dc.relation.ispartofActa Medica Mediterranea
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAcinetobacter Baumanniien_US
dc.subjectBacteremiaen_US
dc.subjectColistinen_US
dc.subjectMonotherapyen_US
dc.subjectMulti-Drug Resistanten_US
dc.subjectSepsisen_US
dc.titleEfficacy of colistin and non-colistin monotherapies in multi-drug resistant acinetobacter baumannii bacteremia/sepsisen_US
dc.titleEfficacy of colistin and non-colistin monotherapies in multi-drug resistant acinetobacter baumannii bacteremia/sepsis
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu